Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: A study protocol

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Sumi, Eriko ^a   Sugie, Tomoharu ^b   Yoshimura, Kenichi ^c   Tada, Harue ^a   Ikeda, Takafumi ^a   Suzuki, Eiji ^a   Tanaka, Yoshimasa ^d   Teramukai, Satoshi ^e   Shimizu, Akira ^a   Toi, Masakazu ^a   Minato, Nagahiro ^f  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^c KOBE UNIVERSITY HOSPITAL   (Japan)

^d NAGASAKI UNIVERSITY   (Japan)

^e KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^f KYOTO UNIVERSITY   (Japan)

Author keywords

Breast cancer; Letrozole; Postmenopausal women; Zoledronic acid; T cells

Indexed keywords

LETROZOLE; ZOLEDRONIC ACID; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; LYMPHOCYTE ANTIGEN RECEPTOR; NITRILE; TRIAZOLE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GAMMA DELTA T LYMPHOCYTE; HUMAN; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; BREAST NEOPLASMS; CLINICAL PROTOCOL; CLINICAL TRIAL; IMMUNOLOGY; PREOPERATIVE CARE; T LYMPHOCYTE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL PROTOCOLS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; NITRILES; POSTMENOPAUSE; PREOPERATIVE CARE; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES; TRIAZOLES;

EID: 84964314598     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0310-2     Document Type: Article

References (28)

1. The Japanese Breast Cancer Society: National Breast Cancer Registry Report 2008. [http://www.jbcs.gr.jp/people/nenjihoukoku/2008nenji.pdf]
2. Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munarriz B, Rodriguez CA, Crespo C, De Alava E, Lopez Garcia-Asenjo JA, Guitian MD, Almenar S, Gonzalez-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Segui MA, Mayordomo JI, Anton A, Baena JM, Plazaola A, Modolell A, Pelegri A, Mel JR, Aranda E, Adrover E, et al: Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst 2008, 100(11):805-814.
3. Early Breast Cancer Trialists' Collaborative G: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365(9472):1687-1717.
4. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005, 23(22):5108-5116.
5. Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, Dube P, de Oliveira CT: Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 2006, 106(10):2095-2103.
6. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M, Letrozole Neo-Adjuvant Breast Cancer Study Group: Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001, 12(11):1527-1532.
7. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl C, Greil R, Austrian Breast Colorectal Cancer Study Group, Vienna Austria: Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011, 12(7):631-641.
8. Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, Von Minckwitz G, Sleeboom HP, Forbes J, Barrios C, Frassoldati A, Campbell I, Paija O, Martin N, Modi A, Bundred N: Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 2013, 24(2):398-405.
9. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R: Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011, 365(15):1396-1405.
10. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, Gil M, Ritchie D, Passos-Coelho JL, Wheatley D, Burkinshaw R, Marshall SJ, Thorpe H, Azure Investigators: The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010, 102(7):1099-1105.
11. Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2(8):584-593.
12. Green JR, Guenther A: The backbone of progress-preclinical studies and innovations with zoledronic acid. Crit Rev Oncol Hematol 2011, 77(Suppl 1):S3-S12.
13. Winter MC, Holen I, Coleman RE: Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008, 34(5):453-475.
14. Sugie T, Murata-Hirai K, Iwasaki M, Morita CT, Li W, Okamura H, Minato N, Toi M, Tanaka Y: Zoledronic acid-induced expansion of gammadelta T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells. Cancer Immunol Immunother 2013, 62(4):677-687.
15. Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR: Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 1995, 375(6527):155-158.
16. Tanaka Y: Human gamma delta T cells and tumor immunotherapy. J Clin Exp Hematop 2006, 46(1):11-23.
17. Miyagawa F, Tanaka Y, Yamashita S, Minato N: Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gamma delta T cells by aminobisphosphonate antigen. J Immunol 2001, 166(9):5508-5514.
18. Kunzmann V, Bauer E, Wilhelm M: Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 1999, 340(9):737-738.
19. The World Medical Association: WMA Declaration of Helsinki -ethical principles for medical research involving human subjects. [http://www. wma.net/en/30publications/10policies/b3/17c.pdf]
20. The Ministry of Health, Labor, and Welfare: ethics guidelines for clinical research. [http://www.mhlw.go.jp/general/seido/kousei/i-kenkyu/ index.html]
21. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247.
22. Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M: A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncol 2012, 13(6):e240-e248.
23. Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M: Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008, 100(19):1380-1388.
24. Breast MRI: guidelines from the European Society of Breast Imaging. [http://www.eusobi.org/cms/website.php?id=/en/society/guidelines.htm]
25. The Japanese Clinical Oncology Group: Japanese version of the Common Terminology Criteria for Adverse Events version 4.0. [http://www.jcog.jp/doctor/tool/ctcaev4.html]
26. Sambucini V: A Bayesian predictive two-stage design for phase II clinical trials. Stat Med 2008, 27(8):1199-1224.
27. Teramukai S, Daimon T, Zohar S: A Bayesian predictive sample size selection design for single-arm exploratory clinical trials. Stat Med 2012, 31(30):4243-4254.
28. A randomized study of adjuvant endocrine therapy with or without chemotherapy for postmenopausal breast cancer patients who responded to neoadjuvant letrozole: An interim efficacy analysis of the new primary endocrine-therapy origination study (NEOS / N-SAS BC06). [http://sabcs.posterview.com/]